Title:
BRAP2 ACTION ENHANCER
Document Type and Number:
WIPO Patent Application WO/2021/075147
Kind Code:
A1
Abstract:
Provided is a novel BRAP2 action enhancer that is useful for inhibiting both the Ras/Raf/MEK/ERK pathway and the PI3K/Akt/mTOR pathway, the BRAP2 action enhancer comprising, as an active ingredient, a compound represented by formula (1) or (2) or a salt thereof.
Inventors:
SHIINA ISAMU (JP)
SHIMONAKA MOTOYUKI (JP)
HASEGAWA GO (JP)
NAGAHARA YUKITOSHI (JP)
SHIMONAKA MOTOYUKI (JP)
HASEGAWA GO (JP)
NAGAHARA YUKITOSHI (JP)
Application Number:
PCT/JP2020/031423
Publication Date:
April 22, 2021
Filing Date:
August 20, 2020
Export Citation:
Assignee:
UNIV TOKYO SCIENCE FOUND (JP)
UNIV TOKYO DENKI (JP)
UNIV TOKYO DENKI (JP)
International Classes:
A61P29/00; A61K31/138; A61K31/40; A61K31/4025; A61K31/4188; A61P31/12; A61P35/00; A61P37/06; A61P43/00; C07D295/088
Domestic Patent References:
| WO2009035020A1 | 2009-03-19 |
Foreign References:
| JP2006117648A | 2006-05-11 |
Other References:
FRANKS LIRIT N., FORD BENJAMIN M., FUJIWARA TOSHIFUMI, ZHAO HAIBO, PRATHER PAUL L.: "The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 353, 2018, pages 31 - 42, XP055819387, ISSN: 0041-008X
HASHIZUME MISATO, OHSUGI YOSHIYUKI: "IL-6 as a target in autoimmune disease and inflammation", FOLIA PHARMACOLOGICA JAPONICA, vol. 144, no. 4, 2014, pages 172 - 177, XP009520560, ISBN: 1347-8397
CRISAFULLI, S. ET AL.: "Potential Role ofAnti‑interleukin (IL)‑6 Drugs intheTreatment ofCOVID‑19: Rationale, Clinical Evidence andRisks", CLINICAL EVIDENCE AND RISKS, BIODRUGS, vol. 34, no. 4, 15 June 2020 (2020-06-15), pages 415 - 422, XP055819391, ISSN: 1173-8804
HASHIZUME MISATO, OHSUGI YOSHIYUKI: "IL-6 as a target in autoimmune disease and inflammation", FOLIA PHARMACOLOGICA JAPONICA, vol. 144, no. 4, 2014, pages 172 - 177, XP009520560, ISBN: 1347-8397
CRISAFULLI, S. ET AL.: "Potential Role ofAnti‑interleukin (IL)‑6 Drugs intheTreatment ofCOVID‑19: Rationale, Clinical Evidence andRisks", CLINICAL EVIDENCE AND RISKS, BIODRUGS, vol. 34, no. 4, 15 June 2020 (2020-06-15), pages 415 - 422, XP055819391, ISSN: 1173-8804
Attorney, Agent or Firm:
SHOBAYASHI Masayuki et al. (JP)
Download PDF:
Previous Patent: OPTICAL TRANSMISSION SYSTEM
Next Patent: PRODUCTION METHOD FOR BIOGAS USING USED SANITARY ARTICLES
Next Patent: PRODUCTION METHOD FOR BIOGAS USING USED SANITARY ARTICLES